Reversible retinal vessel closure from VEGF-induced leukocyte plugging.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JCI Insight

• Publication date

  2017-09-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/jci.insight.95530PMID 28931763PMCID PMC5621911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.

  2016cited by this paper
• Murine fundus fluorescein angiography: An alternative approach using a handheld camera.

  2016cited by this paper
• Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside.

  2016cited by this paper
• Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

  2015cited by this paper
• Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography.

  2015cited by this paper
• Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial.

  2015cited by this paper
• Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.

  2014cited by this paper
• Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion.

  2013cited by this paper
• Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.

  2013cited by this paper
• Long-term effects of ranibizumab on diabetic retinopathy severity and progression.

  2012cited by this paper
• Targeted deletion of Vegfa in adult mice induces vision loss.

  2012cited by this paper
• Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

  2012cited by this paper
• Update on animal models of diabetic retinopathy: from molecular approaches to mice and higher mammals

  2012cited by this paper
• Global Prevalence and Major Risk Factors of Diabetic Retinopathy

  2012cited by this paper
• Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress

  2011cited by this paper
• Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells

  2010cited by this paper
• Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

  2010cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Oxidative stress and diabetic complications.

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Conversion from nonischemic to ischemic retinal vein occlusion: prediction by venous velocity on color Doppler imaging

  2009influential reference
• The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.

  2009influential reference
• A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.

  2009cited by this paper
• Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels

  2008cited by this paper
• The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study.

  2008cited by this paper
• Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives

  2008cited by this paper
• Arteriolar Involvement in the Microvascular Lesions of Diabetic Retinopathy: Implications for Pathogenesis

  2007cited by this paper
• Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

  2007cited by this paper
• TNF-α is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage

  2007cited by this paper
• Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.

  2007cited by this paper
• Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab

  2006cited by this paper
• Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.

  2006cited by this paper
• Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress.

  2006cited by this paper
• Sustained expression after nonviral ocular gene transfer using mammalian promoters

  2006cited by this paper
• Supplemental oxygen improves diabetic macular edema: a pilot study.

  2004cited by this paper
• Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

  2004cited by this paper
• A central role for inflammation in the pathogenesis of diabetic retinopathy

  2004cited by this paper
• Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor.

  2003cited by this paper
• The role of advanced glycation in the pathogenesis of diabetic retinopathy.

  2003cited by this paper
• Nitric oxide in vascular biology

  2003cited by this paper
• Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression

  2002influential reference
• Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment.

  2002cited by this paper
• Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1

  2002cited by this paper
• Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells.

  2001cited by this paper
• Vascular Endothelial Growth Factor Expression of Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), and E-selectin through Nuclear Factor-κB Activation in Endothelial Cells*

  2001cited by this paper
• Leukocyte-mediated endothelial cell injury and death in the diabetic retina.

  2001cited by this paper
• Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition

  1999cited by this paper
• Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition.

  1999cited by this paper
• Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

  1998cited by this paper
• VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR).

  1998cited by this paper
• The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.

  1997cited by this paper
• Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.

  1997cited by this paper
• Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.

  1996cited by this paper
• The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

  1996cited by this paper
• Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

  1996cited by this paper
• Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

  1995cited by this paper
• Oxygen-induced retinopathy in the mouse.

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Experimental retinal branch vein occlusion in miniature pigs induces local tissue hypoxia and vasoproliferative microangiopathy.

  1990cited by this paper
• Partial occlusion of the central retinal vein.

  1983influential reference
• Retinal ischemia in diabetic retinopathy.

  1975influential reference
• Oxygen studies in retrolental fibroplasia. II. The production of the microscopic changes of retrolental fibroplasia in experimental animals.

  1953cited by this paper
• Surface Marker for the Lineage of Monocyte-macrophages in Humans Flt-1, Vascular Endothelial Growth Factor Receptor 1, Is a Novel Cell

  year unknowncited by this paper
• PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS Identi fi cation and characterization of VEGF-A – responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans

  year unknowncited by this paper

• Novel OCT Angiography Parameters for Analyzing Microvascular Changes in Proliferative Diabetic Retinopathy After Intravitreal Conbercept Loading Injections.

  2026cites this paper
• Fibulin-7 and its bioactive fragments: emerging immunomodulatory roles in disease

  2025cites this paper
• Sustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases.

  2025cites this paper
• Causal Associations of Smoking, Alcohol, Obesity, Sedentary Behavior, Hypertension, and Hyperglycemia With Retinal Vein Occlusion: A Mendelian Randomization Study

  2025cites this paper
• Pharmacological depletion of pericytes induces diabetic retinopathy-like abnormal blood vessels in neonatal rat retina.

  2025cites this paper
• Absolute Quantification of Aging-Associated Glycans in IgG for Biological Age Prediction: Insights from Glycomics and Transcriptomics

  2025cites this paper
• Exploration Progress on Inflammatory Responses and Immune Regulatory Mechanisms in Diabetic Retinopathy

  2025cites this paper
• The Effects of Anti-Vascular Endothelial Growth Factor Loading Injections on Retinal Microvasculature in Diabetic Macular Edema

  2024cites this paper
• Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy

  2024cites this paper
• Vascular cell-adhesion molecule 1 (VCAM-1) regulates JunB-mediated IL-8/CXCL1 expression and pathological neovascularization

  2023cites this paper
• Regulation of monocyte activation by PPARα through interaction with the cGAS-STING pathway.

  2023cites this paper
• Perspectives of diabetic retinopathy—challenges and opportunities

  2022cites this paper
• Analysis of the Cytokine Expression in the Aqueous Humor of Individuals with BRVO-Associated Macular Edema

  2022cites this paper
• Hematopoietic Cells Influence Vascular Development in the Retina

  2022cites this paper
• [Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion].

  2022cites this paper
• Retinal non-perfusion in diabetic retinopathy

  2022cites this paper
• The Changes of Irisin and Inflammatory Cytokines in the Age-Related Macular Degeneration and Retinal Vein Occlusion

  2022cites this paper
• Study of Nonperfusion Area Changes after Ranibizumab Intravitreal Injection for Diabetic Macular Edema by Means of Widefield OCT Angiography

  2022influential citation
• Microvascular Structure Changes After Intravitreal Ranibizumab Injection in Retinal Vein Occlusion Patients With and Without Macular Ischemia

  2021cites this paper
• AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation

  2021cites this paper
• Investigation of the mechanisms of VEGF-mediated compensatory lung growth: the role of the VEGF heparin-binding domain

  2021cites this paper
• Anatomic–Functional Correlates in Lesions of Retinal Vein Occlusion

  2021cites this paper
• Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)

  2021cites this paper
• Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy

  2021cites this paper
• Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture

  2021cites this paper
• Retinal vascular occlusions.

  2020cites this paper
• Ursodeoxycholic Acid Attenuates the Retinal Vascular Abnormalities in Anti-PDGFR-β Antibody-Induced Pericyte Depletion Mouse Models

  2020cites this paper
• Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles

  2020cites this paper
• Fibulin-7 C-terminal fragment and its active synthetic peptide suppress choroidal and retinal neovascularization.

  2020cites this paper
• Hepatocyte growth factor is upregulated in ischemic retina and contributes to retinal vascular leakage and neovascularization

  2020cites this paper
• Foveal avascular zone area analysis in juvenile-onset type 1 diabetes using optical coherence tomography angiography

  2020cites this paper
• Re: Couturier et al.: Widefield OCT-angiography and fluorescein angiography assessments of nonperfusion in diabetic retinopathy and edema treated with anti-vascular endothelial growth factor (Ophthalmology. 2019;126:1685-1694).

  2020cites this paper
• Suppression of Ocular Vascular Inflammation through Peptide-Mediated Activation of Angiopoietin-Tie2 Signaling

  2020cites this paper
• A Custom-Made Semiautomatic Analysis of Retinal Nonperfusion Areas After Dexamethasone for Diabetic Macular Edema

  2020cites this paper
• SCORE2 Report 13: Intraretinal Hemorrhage Changes in Eyes with Central or Hemiretinal Vein Occlusion Managed with Aflibercept, Bevacizumab or Observation. Secondary Analysis of the SCORE and SCORE2 Clinical Trials.

  2020cites this paper
• Clinical effect of conbercept on improving diabetic macular ischemia by OCT angiography

  2020cites this paper
• Aflibercept ameliorates retinal pericyte loss and restores perfusion in streptozotocin-induced diabetic mice

  2020cites this paper
• Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study)

  2020cites this paper
• The Role of Inflammation in Diabetic Retinopathy

  2020cites this paper
• Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases.

  2020cites this paper
• One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study

  2019cites this paper
• Molecular mechanisms of retinal ischemia.

  2019cites this paper
• Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.

  2019cites this paper
• Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.

  2019cites this paper
• Gene expression patterns of COX-1, COX-2 and iNOS in H. Pylori infected histopathological conditions.

  2019cites this paper
• Changes in Macular and Peripheral Perfusion Following Anti-vascular Endothelial Growth Factor Treatment for Patients with Diabetic Retinopathy

  2019cites this paper
• Growth factor signaling pathways in vascular development and disease

  2019cites this paper
• Branch Retinal Vein Occlusion: Treatment Outcomes According to the Retinal Nonperfusion Area, Clinical Subtype, and Crossing Pattern

  2019cites this paper
• Recent advances in understanding and managing retinal vein occlusions

  2018cites this paper
• Microvascular Complications in the Eye: Diabetic Retinopathy

  2018cites this paper
• Retinal flow density by optical coherence tomography angiography is useful for detection of nonperfused areas in diabetic retinopathy

  2018cites this paper
• Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial.

  2018cites this paper